CHARLOTTE, NC, January 24, 2022 – (BUSINESS WIRE) – cbdMD, Inc. (NYSE American: YCBD, YCBDpA), one of the world’s leading and most trusted and recognized CBD health and wellness companies, announced today that it will host a conference call at 4:15 p.m., Eastern Time. Thursday, February 10, 2022, to discuss the first quarter financial results and business progress of the company on December 31, 2021.
CONFERENCE DETAILS
Thursday, February 10, 2022, 4:15 p.m., Eastern Time | |
National: | 888-506-0062 |
International: 
| 973-528-0011 |
Access code: | 623328 |
Repeating the conference call: available until March 12, 2022 | |
National: | 877-481-4010 
|
International: | 919-882-2331 |
Play password:
| 44450 |
Webcast / Webcast Replay link: available until February 10, 2023: https://www.webcaster4.com/Webcast/Page/2206/44450 | |
About cbdMD, Inc.
cbdMD, Inc. is one of the leading and most trusted and recognized cannabidiol (CBD) brands with a full line of THC1-free CBD products produced in the United States, as well as our new Full Spectrum products. Currently, our cbdMD brand includes more than 130 SKUs of high quality CBD products, such as CBD tinctures, CBD jelly beans, CBD topicals, CBD capsules, CBD bath pumps, CBD bath salts, CBD sleeping pills and CBD beverage mixes. Our Paw CBD pet product brand includes over 45 SKUs of veterinary formulated products that include tinctures, chews, topical products in different concentrations, and our CBD Botanicals skin care and beauty product brand includes 15 SKUs , which include facial oil and serum, toners and moisturizers. , fair skin, facial masks, scrubs and body care. To learn more about cbdMD and its full line of CBD-free CBC oil products in the United States and full spectrum products, visit www.cbdmd.com, follow cbdMD on Instagram and Facebook, or visit one of 6,000 outlets offering cbdMD. products.
Prospective statements
This press release contains certain forward-looking statements that are based on current expectations and involve certain risks and uncertainties within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by using for words such as ” should ”, ” may, ” ” intend ”, ” anticipate ”, ” believe ”, ” estimate ”, ” projects, ” ” forecasts, ” ” wait ”, ” plan ” and ” propose ”. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict and may cause actual results to differ materially from those expressed or forecast in the forward-looking statements. , including, without limitation, the statements made regarding the expansion of the consumer market for CBD products and our ability to increase our market share, our limited operating history, our ability to expand our ss business and significantly increase our revenue, our ability to effectively leverage our brand partnerships and sponsorships, our ability to compete effectively in our market, our ability to achieve our net sales guidance and our ability to report on profitable operations in the future. We urge you to carefully review and consider any warnings and other disclosures, including statements made under the heading “Risk Factors” in the cbdMD, Inc. Annual Report. on Form 10-K for the fiscal year ended September 30, 2021 as filed with the Securities and Exchange Commission (the “SEC”) and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those of forward-looking statements, many of which are generally beyond the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. assumes no obligation to update any forward-looking statements unless required by law. The information on our websites and social media platforms, including Instagram and Facebook, is not part of this press release.
The story goes on
1 Without THC is defined as below the detection level using validated scientific analytical tools.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20220124005715/ca/
Contacts
PR:
cbdMD, Inc.
Robert Pettway
Director of Public Relations
rpettway@cbdmd.com
(423) 503-5225
Investors:
cbdMD, Inc.
John Weston
Director of Investor Relations
john.weston@cbdmd.com
(704) 249-9515
